Forte Biosciences (NASDAQ:FBRX) Sees Large Volume Increase – Still a Buy?

Posted by Brian Himes on Aug 6th, 2026

Shares of Forte Biosciences, Inc. (NASDAQ:FBRX – Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 655,893 shares traded hands during mid-day trading, an increase of 13% from the previous session’s volume of 578,546 shares.The stock last traded at $76.7950 and had previously closed at $76.61.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on FBRX shares. Barclays lowered shares of Forte Biosciences from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $74.00 to $77.00 in a report on Tuesday, July 28th. Weiss Ratings cut Forte Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Evercore set a $77.00 price target on shares of Forte Biosciences in a research report on Monday, July 27th. Wall Street Zen cut Forte Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 25th. Finally, TD Cowen cut shares of Forte Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, July 27th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Forte Biosciences currently has a consensus rating of “Hold” and a consensus target price of $72.50.

View Our Latest Stock Analysis on FBRX

Forte Biosciences Stock Performance

The firm has a market capitalization of $1.07 billion, a PE ratio of -16.55 and a beta of 2.62. The firm’s 50 day moving average price is $35.05 and its 200-day moving average price is $30.60.

Forte Biosciences (NASDAQ:FBRX – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.08). On average, equities research analysts expect that Forte Biosciences, Inc. will post -4.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE increased its stake in shares of Forte Biosciences by 444.0% during the first quarter. Bank of America Corp DE now owns 21,606 shares of the company’s stock worth $560,000 after buying an additional 17,634 shares during the period. Stempoint Capital LP acquired a new stake in shares of Forte Biosciences during the first quarter worth $1,503,000. Royal Bank of Canada boosted its holdings in Forte Biosciences by 11.7% in the 1st quarter. Royal Bank of Canada now owns 13,389 shares of the company’s stock valued at $346,000 after purchasing an additional 1,403 shares in the last quarter. Candriam S.C.A. acquired a new stake in Forte Biosciences in the first quarter valued at $2,196,000. Finally, Quadrature Capital Ltd purchased a new stake in Forte Biosciences in the 4th quarter valued at approximately $479,000. Institutional investors and hedge funds own 77.63% of the company’s stock.

Forte Biosciences Company Profile

(Get Free Report)

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.